• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Immuron Ltd ADR (NQ: IMRN )

    1.920 UNCHANGED
    Streaming Delayed Price Updated: 1:31 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Immuron Ltd ADR

    < Previous 1 2 3 4 5 6 Next >
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
    Pre-market stock movers are worth checking out on Thursday to get an idea of the hottest stocks worth watching this morning! 
    Via InvestorPlace
    Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US
    From Immuron Limited
    Via GlobeNewswire
    Immuron welcomes launch of Travelan on Amazon US
    --News Direct-- 
    Via News Direct
    Immuron Presentation Australian Biologics Festival 2024
    From Immuron Limited
    Via GlobeNewswire
    Immuron achieves record Travelan® sales
    From Immuron Limited
    Via GlobeNewswire
    Immuron CEO, Steven Lydeamore Investor Webinar Presentation
    From Immuron Limited
    Via GlobeNewswire
    Immuron achieves record half yearly Travelan® sales
    From Immuron Limited
    Via GlobeNewswire
    Immuron Clinical Trials Update
    From Immuron Limited
    Via GlobeNewswire
    Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study
    From Immuron Limited
    Via GlobeNewswire
    Immuron CEO, Steven Lydeamore Investor Webinar Presentation
    From Immuron Limited
    Via GlobeNewswire
    Immuron CEO Steven Lydeamore Investor Webinar Presentation
    From Immuron Limited
    Via GlobeNewswire
    Immuron CEO Steven Lydeamore presented at AusBioInvest
    From Immuron Limited
    Via GlobeNewswire
    Immuron Announces Travelan® Clinical Study Cohort 2 commences
    From Immuron Limited
    Via GlobeNewswire
    Immuron achieves record quarterly Travelan® sales
    From Immuron Limited
    Via GlobeNewswire
    Immuron hails record monthly sales of Travelan
    Immuron Ltd (NASDAQ:IMRN, ASX:IMC) CEO Steve Lydeamore speaks with Proactive following news the company has achieved record monthly sales of its over-the-counter gastrointestinal supplement Travelan®.... 
    Via TheNewswire.com
    Immuron hails record monthly sales of Travelan
    --News Direct-- 
    Via News Direct
    Immuron achieves record monthly Travelan® sales
    From Immuron Limited
    Via GlobeNewswire
    Immuron CEO, Steven Lydeamore to present at H.C. Wainwright
    From Immuron Limited
    Via GlobeNewswire
    Immuron to present at the Military Health System Research Symposium
    From Immuron Limited
    Via GlobeNewswire
    Immuron welcomes launch of Travelan on Amazon US
    Immuron Ltd (NASDAQ:IMRN, ASX:IMC) chief commercial officer Flavio Palumbo speaks with Proactive following the news its Travelan product has launched on Amazon US. 
    Via TheNewswire.com
    Immuron Announces First Patients Enrolled in Travelan® Clinical Study
    From Immuron Limited
    Via GlobeNewswire
    Immuron CEO, Steven Lydeamore to present at Bioshares
    From Immuron Limited
    Via GlobeNewswire
    Immuron Business Update - Ateria Health launches Juvia™ in Australia
    From Immuron Limited
    Via GlobeNewswire
    Immuron FY23 Sales increase 136% on FY22 Sales
    From Immuron Limited
    Via GlobeNewswire
    Immuron Chairman Transition
    From Immuron Limited
    Via GlobeNewswire
    Immuron Business Update: Letter to Shareholders
    From Immuron Limited
    Via GlobeNewswire
    Immuron Initiates Recruitment of Travelan® Clinical Study
    From Immuron Limited
    Via GlobeNewswire
    Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027
    Palm Beach, FL – May 9, 2023 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that attacks the brain’s nerve cells or neurons, which... 
    Via FinancialNewsMedia
    Topics Intellectual Property
    Exposures Intellectual Property
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.